Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Resources

PER Pulse™ Recaps highlight key elements of the Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers online CME activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers

Release Date: May 30, 2017
Expiration Date: May 30, 2018
Media: Internet - based

 

Activity Overview

This edition of Medical Crossfire®, filmed in conjunction with the 34th Annual Miami Breast Cancer Conference®, has been designed to facilitate the exchange of ideas and explore best practices regarding the potential impact of poly ADP ribose polymerase (PARP) inhibitors on the treatment landscape for patients with cancer. The time is now for clinicians to get up-to-date on the rationale for the use of PARP inhibitors in breast cancer, as well as the established and emerging clinical data supporting their use.

Our activity chair, Mark Robson, MD, and our expert faculty will each present brief overviews of key topics related to PARP inhibitors in the treatment of cancer, including their rationale, resistance mechanisms to PARP inhibition, their use in different treatment strategies, and the role of genetic testing when considering the use of PARP inhibitors. Engaging panel discussions will occur throughout this activity.

  

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Requirements for Successful Completion

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward all attendees of the 34th Annual Miami Breast Cancer Conference®, including medical, radiation, and surgical oncologists whose primary practice focus is breast cancer. Participants will be primarily oncologists or fellows-in-training whose practices require mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the treatment and management of breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Explain tumor biology mechanisms that provide the rationale for targeting PARP in the treatment of cancers
  • Assess emerging data concerning the application of PARP inhibitors in the treatment of breast cancer and how this applies to personalization of management/counseling for patients with these tumors and their families
  • Apply lessons learned from PARP inhibitor strategies for ovarian cancer in the context of an evolving treatment landscape for patients with breast cancer


Faculty, Staff, and Planners' Disclosures

Chair:

Mark Robson, MD
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosure: Consultant: AstraZeneca; Institutional Research Support: AbbVie, Astra-Zeneca, Biomarin, Medivation, Myriad

Faculty:

Kimberly Blackwell, MD
Professor of Medicine
Assistant Professor of Radiation Oncology
Duke University Medical Center
Director of the Breast Cancer Program
Duke Cancer Institute
Durham, NC

Disclosure: Grant/Research Support: Celgene, Genentech, Pfizer, Novartis; Consultant: Advaxis, Bayer, Celgene, Coherus, Eli Lilly, Genentech, Incyte Corp, MacroGenics, Merck, Novartis, Pfizer, Pierian Biosciences, Puma, Roche, Sandoz

Sara Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co- Director, Santa Monica – UCLA Outpatient Hematology/Oncology Practice
Associate Professor of Medicine, Division of Hematology/Oncology,
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure: Grant/Research Support: Amgen, Bayer, BI, Genentech, GSK, Pfizer, Roche, Biomarin, Merrimack, OBI Pharm, PUMA, Dignitana, Medivation, Lilly, Novartis, OBI; Travel- Lilly, Novartis, OBI

Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosure: Grant/ Research Support: Novartis; Consultant: Nektar, Novartis, Puma

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By